Limited Liability Company

What Limited Liability Company does

SIA LMP is a privately held Latvian pharmaceutical manufacturer, founded 8 April 1992 and headquartered at 1 Vietalvas Street, Riga. The company develops, manufactures, and sells finished topical dosage forms — solutions, gels, creams, and ointments — targeting skin lesions, mucous membrane diseases, upper respiratory tract conditions, muscle and joint pain, allergic reactions, fungal infections, and parasitic conditions (scabies and pediculosis). Its portfolio spans seven therapeutic categories and 15+ products, including branded lines such as Ortofēna (diclofenac gel), Ibuprofēns LMP, Brūču (methyluracil/lidocaine wound healing ointment), Sanagels, Stomagels, Pretniezes (diphenhydramine antipruritic gel), Pretsēnīšu (undecylenic acid antifungal), Pedeks and Permetrīns LMP (permethrin pediculicides/scabicides), and Virogels (nasal antiviral gel). Thirteen products are registered in the Latvian medicines register, with three additional cosmetics or medical devices.

Manufacturing is conducted at a single GMP-compliant site in Riga with an in-house Quality Control laboratory. The company has held an unlimited drug manufacturing license since 24 October 2007 and has been GMP-compliant since 2004, with the manufacturing authorization issued by Latvian regulatory authorities. Products reach end consumers through wholesale distribution to registered pharmacies and through internet pharmacy platforms including Apotheka, Benu, Maija Aptieka, Euroaptieka, and E-Saules Aptieka in Latvia.

LMP generates revenue primarily through B2B pharmaceutical product sales of finished dosage forms, sold via wholesale distribution and exported to 26+ countries across Europe, Asia (Taiwan, UAE, Armenia, Azerbaijan, Georgia, Kazakhstan), and Africa (Cabo Verde, Mozambique) under distributor agreements. Pricing is not publicly disclosed and is set through pharmacy retail channels. The company participates in international pharmaceutical trade shows (CPHI series in Frankfurt, Barcelona, Milan, Malaysia) to source new international distribution partners and has accessed EU/ERDF-funded support programmes in 2011, 2016, and 2024 for workforce training, international competitiveness, and innovative SME development. Revenue figures are not publicly disclosed.

Name

Limited Liability Company

Legal name

Sabiedrība ar ierobežotu atbildību "LMP"

Website

https://lmp.lv

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Short description

SIA LMP is a Latvian pharmaceutical manufacturer (founded 1992) that develops, produces, and sells topical dosage forms — solutions, gels, creams, and ointments — for skin, mucosal, respiratory, and pain conditions, distributing 15+ products domestically and to 26+ countries via wholesale and pharmacy channels.

Ownership category

akta.pro rank

Product category

Topical Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)

akta.pro secondary industries

OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC), Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC)

Keywords

• Topical pharmaceutical manufacturing
• Dermatological gels and creams
• Wound healing ointments
• Antifungal gel formulations
• Pediculicide and scabicide treatments

Headquarters

HQ city

Riga

HQ country

Latvia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Sale of finished pharmaceutical dosage forms (solutions, gels, creams, ointments) for topical use. Products treat skin lesions, mucous membrane diseases, upper respiratory tract conditions, and muscle pain. Both domestic (Latvian) and export sales to over 26 countries.
2. Wholesale Distribution: Distribution to registered wholesalers and pharmacies. The company sells to pharmaceutical distributors who then supply pharmacies and medical institutions.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

SIA LMP develops, manufactures and sells finished pharmaceutical dosage forms for topical use — solutions, gels, creams and ointments — used to treat skin lesions, mucous membrane diseases, upper respiratory tract conditions, muscle and joint pain, allergic reactions, fungal infections, and pediculosis/scabies. Products are manufactured at a GMP-compliant facility in Riga and sold both domestically in Latvia and through export distribution partners in more than 26 countries.

Product overview

LMP is a Latvian pharmaceutical manufacturing company that develops, manufactures, and sells finished dosage forms for topical use — solutions, gels, creams, and ointments. The company produces over 15 pharmaceutical products including analgesics (Ibuprofen LMP gel, Ortofen gel with diclofenac), wound healing products (Brūču ointment, Sanagels, Stomagels), anti-itch preparations (Pretniezes gel), topical antifungals (Pretsēnīšu gel), pediculicides and scabicides (Pedeks solution and gel, Permethrin LMP gels), and nasal antiviral gels (Virogels). These quality products target skin lesions, mucous membrane diseases, upper respiratory tract conditions, and pain relief from trauma. The product portfolio spans seven therapeutic categories: joint/muscle pain relief, wound/ulcer treatment, oral mucosal disease treatment, anti-allergy, dermatological antifungals, pediculosis/scabies treatment, and rhinological/antiflu preparations. Products are sold in Latvia and exported to over 25 countries including EU member states and other international markets.

Differentiator

Problem solved

Functional benefit

Products and services

• ORTOFĒNA 10 mg/g gels

Quantifiable outcome

• Over 30 years of pharmaceutical manufacturing experience
• +1 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered moderate.

• LIAA (Latvian Investment and Development Agency)moderateStrategic or Co-development Partner · 1 January 2024SIA LMP signed agreement No. 17.1-1-L-2024/82 with LIAA in 2024 for innovative SME development support under EU Cohesion Policy Programme 2021-2027, aiming to promote sustainable growth, competitiveness and job creation.
• LIAA (Latvian Investment and Development Agency)moderateStrategic or Co-development Partner · 25 April 2016SIA LMP signed agreement No. SKV-L-2016/135 on April 25, 2016 with LIAA for international competitiveness support, co-financed by the European Regional Development Fund.
• LAĶĪFA (Latvian Chemistry and Pharmacy Entrepreneurs Association)moderateStrategic or Co-development Partner · 6 January 2011Association 'Latvian Chemistry and Pharmacy Entrepreneurs Association' (LAĶĪFA) and LIAA signed agreement No. L-APA-10-0025 on January 6, 2011 for employee training and qualification improvement project. LMP participated in this ESF-funded project for training in production engineering, IT, engineering, manufacturing, occupational safety, and language programs.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Galderma: Global dermatology-focused pharmaceutical company producing prescription and OTC topical formulations (creams, gels, ointments). Highly relevant adjacency given LMP's dermatology OTC orientation.
• Stada Arzneimittel: Large European generics and OTC company with extensive topical portfolio (creams, gels, ointments) and strong pharmacy distribution across EU and CIS. Competes with LMP in many of the same export markets and product categories.
• Bayer Consumer Health: Major OTC player with leading topical pain-relief (diclofenac gel) and dermatology brands. Comparable as a competing supplier of topical NSAIDs and OTC dermatology products in European pharmacy channels.
• Teva Pharmaceutical Industries: Global generic manufacturer with broad dermatology and pain-relief topical portfolio. Sets pricing benchmarks for commoditized molecules such as diclofenac and permethrin in markets where LMP competes.
• HEALDERM / Pharmaceutical Works Polpharma: Polish-based manufacturer of generic and OTC dermatology/topical products with strong distribution in CEE, CIS, and the Baltics. Directly comparable on product format (creams, ointments, gels) and regional distribution footprint.

Regional players

• Vertex Pharmaceuticals (Latvia) / Saules Aptieka chain supplier base: Local Latvian pharmacy distribution and retail channel partners that stock competing Latvian-manufactured OTC products, including Benu, Meness, and Euroaptieka chains' in-house and third-party topical brands. Useful reference for Latvian distribution and pricing dynamics.

Direct peers

• Grindeks: Largest Latvian pharmaceutical manufacturer producing finished dosage forms (tablets, ointments, gels, solutions) with a strong export focus across the CIS and EU. Most direct comparable in terms of home market, product format, and export geography.
• Medochemie: Cyprus-headquartered generic pharmaceutical manufacturer exporting finished dosage forms to Eastern Europe, CIS, Africa, and the Middle East. Comparable in terms of export-driven business model and broad generic topical portfolio.
• Olainfarm: Latvian finished-dose pharmaceutical manufacturer with broad portfolio of generics and OTC products exported to CIS and EU markets. Comparable as a Latvian-headquartered finished-dose manufacturer with multi-country distribution.
• Belupo: Croatian manufacturer of generic and OTC dermatological/topical products with strong distribution across CEE and the Balkans. Similar mid-sized finished-dose manufacturer profile targeting regional and EU export markets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/sia_lmp
• LinkedInlinkedin.com/company/sia-lmp

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Limited Liability Company